12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brilinta regulatory update

AstraZeneca said Australia issued a decision to reimburse cardiovascular drug Brilinta ticagrelor on the Pharmaceutical Benefits Scheme (PBS) to prevent cardiovascular deaths and recurrent events...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >